Oncology Best Practice™: Optimal Patient Management for HER2+ Breast Cancer: Navigating ILD and Other Treatment-Related Side Effects

October 31, 2020

Overview

The introduction of HER2-targeted antibody-drug conjugates (ADCs) has substantially improved outcomes for patients with HER2+ breast cancer in the setting of both early-stage and advanced/metastatic disease. There are currently 2 HER2-directed ADCs that have been approved by the FDA, and several others are in various stages of development in clinical trials. A better understanding of the mechanism of action of ADCs is essential for practitioners to understand the rationale and clinical evidence supporting their use in HER2+ breast cancer to further improve patient outcomes. It is equally important for clinicians to be familiar with the toxicity profiles of these therapies, particularly infrequent but potentially serious adverse events, such as interstitial lung disease (ILD), seen with some ADCs. This activity is designed to educate clinicians on how to monitor for and recognize clinically relevant adverse events associated with HER2-targeted therapies and to develop appropriate mitigation strategies, so that patients are able to derive optimal benefit from their therapies.

Benefits of Attending

• Review the latest safety and efficacy data from clinical trials evaluating HER2-targeted ADCs for patients with HER2+ breast cancer
• Identify key signs and symptoms of significant treatment-related adverse events associated with HER2-targeted agents
• Gain expert insights into best practices for monitoring and managing clinically relevant adverse events associated with HER2-targeted therapies for breast cancer
• Learn how to educate your patients about the potential side effects of their treatments, and steps they should take to ensure prompt diagnosis and management

Target Audience

This activity is directed toward medical, surgical, and radiation oncologists who treat or manage patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, researchers, pathologists, pharmacists and other health care professionals interested in the treatment or management of these tumors are also invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Examine the mechanistic rationale supporting the role of HER2-directed ADCs in breast cancer
• Discuss recent safety and efficacy data pertaining to the application of HER2-directed ADC therapies in metastatic breast cancer
• Identify strategies to effectively manage ILD and other treatment-related adverse events associated with HER2-directed therapies in the treatment of patients with metastatic breast cancer
• Review effective counseling strategies for patients with breast cancer who are being treated with novel HER2-directed therapies

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Program Chair

Ian E. Krop, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Associate Chief, Division of Breast Oncology
Susan F. Smith Center for Women's Cancers
Clinical Research Director, Breast Oncology Center
Dana-Farber Cancer Institute
Boston, MA